EXPEDITED REVIEW: VIEWPOINT
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate RiskMoving an Inflammatory Hypothesis Toward Consensus
Paul M. Ridker, MD, MPH, FACC*
Center for Cardiovascular Disease Prevention, the Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women's Hospital, the Harvard Medical School, and the Harvard School of Public Health, Boston, Massachusetts
Manuscript received January 31, 2007;
revised manuscript received February 13, 2007,
accepted February 13, 2007.
* Reprint requests and correspondence: Dr. Paul M Ridker, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, Massachusetts 02215. (Email: pridker{at}partners.org).
Over 20 large-scale prospective studies show that the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) is an independent predictor of future cardiovascular events that additionally predicts risk of incident hypertension and diabetes. In many studies, the relative impact of hsCRP is at least as large as that individually of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure, or smoking, and knowledge of hsCRP correctly reclassifies a substantial proportion of "intermediate-risk" individuals into clinically relevant higher- or lower-risk categories. Other studies show the relative benefit of statins to be greater among those with increased hsCRP and that achieved hsCRP levels after statin therapy predict recurrent event rates as much as achieved levels of low-density lipoprotein cholesterol. Nonetheless, it remains controversial whether the time has come to modify traditional algorithms used for global risk detection. As described here, 6 areas of controversy regarding hsCRP are resolvable with a consensus position that focuses in primary prevention on selective use among individuals with 5% to 20% 10-year risk as estimated by Adult Treatment Panel III, and focuses in secondary prevention on high-risk patients being treated with statin therapy. Forthcoming trial data could expand or contract this "screen selectively" policy, and investigators should be open to the possibility that second-generation inflammatory biomarkers may be developed that supplant hsCRP altogether. In the meantime, however, this consensus position on hsCRP should be one to which both advocates and critics of the inflammatory hypothesis of atherosclerosis can adhere because it is one that can immediately improve patient care.
|
Abbreviations and Acronyms
| | ATP = Adult Treatment Panel III | | HDL = high-density lipoprotein | | hsCRP = high-sensitivity C-reactive protein | | LDL = low-density lipoprotein | | ROC = receiver-operator characteristic |
|
Related Article
-
High-Sensitivity C-Reactive Protein in Every Chart?: The Use of Biomarkers in Individual Patients
- Ori Ben-Yehuda
J. Am. Coll. Cardiol. 2007 49: 2139-2141.
[Abstract]
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Raposeiras-Roubin, C. B. Pardal, B. R. Janeiro, E. Abu-Assi, J. M. Garcia-Acuna, and J. R. Gonzalez-Juanatey
High-Sensitivity C-Reactive Protein is a Predictor of In-Hospital Cardiac Events in Acute Myocardial Infarction Independently of GRACE Risk Score
Angiology,
January 1, 2012;
63(1):
30 - 34.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Edwards, J. Whittle, and G. L. Ackland
Biomarkers to guide perioperative management
Postgrad. Med. J.,
August 1, 2011;
87(1030):
542 - 549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Martinson, J. O. Teitler, and N. E. Reichman
Health Across the Life Span in the United States and England
Am. J. Epidemiol.,
April 15, 2011;
173(8):
858 - 865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mohlenkamp, N. Lehmann, S. Moebus, A. Schmermund, N. Dragano, A. Stang, J. Siegrist, K. Mann, K.-H. Jockel, R. Erbel, et al.
Quantification of Coronary Atherosclerosis and Inflammation to Predict Coronary Events and All-Cause Mortality
J. Am. Coll. Cardiol.,
March 29, 2011;
57(13):
1455 - 1464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Tzounis, A. Rodriguez-Mateos, J. Vulevic, G. R. Gibson, C. Kwik-Uribe, and J. P. Spencer
Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study
Am J Clin Nutr,
January 1, 2011;
93(1):
62 - 72.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Liu and M. S. Wicha
Targeting Breast Cancer Stem Cells
J. Clin. Oncol.,
September 1, 2010;
28(25):
4006 - 4012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Muraki, T. Tanigawa, K. Yamagishi, S. Sakurai, T. Ohira, H. Imano, A. Kitamura, M. Kiyama, S. Sato, T. Shimamoto, et al.
Nocturnal intermittent hypoxia and C reactive protein among middle-aged community residents: a cross-sectional survey
Thorax,
June 1, 2010;
65(6):
523 - 527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. B. Abdul-Salam, P. Ramrakha, U. Krishnan, D. R. Owen, J. Shalhoub, A. H. Davies, T. Y. Tang, J. H. Gillard, J. J. Boyle, M. R. Wilkins, et al.
Identification and Assessment of Plasma Lysozyme as a Putative Biomarker of Atherosclerosis
Arterioscler Thromb Vasc Biol,
May 1, 2010;
30(5):
1027 - 1033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. N. Deliargyris
Intravascular Ultrasound Virtual Histology Derived Thin Cap Fibroatheroma: Now You See It, Now You Don't...
J. Am. Coll. Cardiol.,
April 13, 2010;
55(15):
1598 - 1599.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Nordestgaard, A. S. Adourian, J. J. Freiberg, Y. Guo, P. Muntendam, and E. Falk
Risk Factors for Near-Term Myocardial Infarction in Apparently Healthy Men and Women
Clin. Chem.,
April 1, 2010;
56(4):
559 - 567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. N. Kim, S. Kim, S. J. Yang, H. J. Yoo, J. A Seo, S. G. Kim, N. H. Kim, S. H. Baik, D. S. Choi, and K. M. Choi
Vascular Inflammation in Patients With Impaired Glucose Tolerance and Type 2 Diabetes: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
Circ Cardiovasc Imaging,
March 1, 2010;
3(2):
142 - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Kaski
C-reactive protein improves risk prediction in patients with acute coronary syndrome, or does it?
Eur. Heart J.,
February 1, 2010;
31(3):
274 - 277.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Belfort, R. Berria, J. Cornell, and K. Cusi
Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
J. Clin. Endocrinol. Metab.,
February 1, 2010;
95(2):
829 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Libby, P. M. Ridker, G. K. Hansson, and for the Leducq Transatlantic Network on Atherothro
Inflammation in Atherosclerosis: From Pathophysiology to Practice
J. Am. Coll. Cardiol.,
December 1, 2009;
54(23):
2129 - 2138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Devaraj, J.-M. Yun, G. Adamson, J. Galvez, and I. Jialal
C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction
Cardiovasc Res,
December 1, 2009;
84(3):
479 - 484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Koike, S. Kitajima, Y. Yu, K. Nishijima, J. Zhang, Y. Ozaki, M. Morimoto, T. Watanabe, S. Bhakdi, Y. Asada, et al.
Human C-Reactive Protein Does Not Promote Atherosclerosis in Transgenic Rabbits
Circulation,
November 24, 2009;
120(21):
2088 - 2094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. Rajpathak, D. J. Kumbhani, J. Crandall, N. Barzilai, M. Alderman, and P. M. Ridker
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Diabetes Care,
October 1, 2009;
32(10):
1924 - 1929.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Khera, G. L. Vega, S. R. Das, C. Ayers, D. K. McGuire, S. M. Grundy, and J. A. de Lemos
Sex Differences in the Relationship between C-Reactive Protein and Body Fat
J. Clin. Endocrinol. Metab.,
September 1, 2009;
94(9):
3251 - 3258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Burioni, F. Canducci, D. Saita, M. Perotti, N. Mancini, D. De Marco, N. Clementi, A. Chieffo, M. Denaro, D. Cianflone, et al.
Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques
J. Immunol.,
August 15, 2009;
183(4):
2537 - 2544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Korngold, J. L. Januzzi Jr, M. L. Gantzer, M.V. Moorthy, N. R. Cook, and C. M. Albert
Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein as Predictors of Sudden Cardiac Death Among Women
Circulation,
June 9, 2009;
119(22):
2868 - 2876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker
Myocardial Infarction in a 72-Year-Old Woman with Low LDL-C and Increased hsCRP: Implications for Statin Therapy
Clin. Chem.,
February 1, 2009;
55(2):
369 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. SHISHEHBOR and S. L. HAZEN
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Cleveland Clinic Journal of Medicine,
January 1, 2009;
76(1):
37 - 44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Spatz, M. E. Canavan, and M. M. Desai
From Here to JUPITER: Identifying New Patients for Statin Therapy Using Data From the 1999-2004 National Health and Nutrition Examination Survey
Circ Cardiovasc Qual Outcomes,
January 1, 2009;
2(1):
41 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Eickhoff, A. Valipour, D. Kiss, M. Schreder, L. Cekici, K. Geyer, R. Kohansal, and O. C. Burghuber
Determinants of Systemic Vascular Function in Patients with Stable Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
December 15, 2008;
178(12):
1211 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Jeppesen, T. W. Hansen, M. H. Olsen, S. Rasmussen, H. lbsen, C. Torp-Pedersen, P. R. Hildebrandt, and S. Madsbad
C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study
European Journal of Cardiovascular Prevention & Rehabilitation,
October 1, 2008;
15(5):
594 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bankier, J. Barajas, A. Martinez-Rumayor, and J. L. Januzzi
Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients
Eur. Heart J.,
September 2, 2008;
29(18):
2212 - 2217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chonchol, G. Lippi, M. Montagnana, M. Muggeo, and G. Targher
Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis
Nephrol. Dial. Transplant.,
September 1, 2008;
23(9):
2879 - 2883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker
The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?
Arterioscler Thromb Vasc Biol,
July 1, 2008;
28(7):
1222 - 1224.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hubel, R. W. Powers, S. Snaedal, H. S. Gammill, R. B. Ness, J. M. Roberts, and R. Arngrimsson
C-Reactive Protein Is Elevated 30 Years After Eclamptic Pregnancy
Hypertension,
June 1, 2008;
51(6):
1499 - 1505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tzoulaki, M.-R. Jarvelin, A.-L. Hartikainen, M. Leinonen, A. Pouta, M. Paldanius, A. Ruokonen, D. Canoy, U. Sovio, P. Saikku, et al.
Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: northern Finland 1966 birth cohort study
Eur. Heart J.,
April 9, 2008;
(2008)
ehn105v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mackman and M. B. Taubman
Does Tissue Factor Expression by Vascular Smooth Muscle Cells Provide a Link Between C-Reactive Protein and Cardiovascular Disease?
Arterioscler Thromb Vasc Biol,
April 1, 2008;
28(4):
601 - 603.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Koenig, N. Khuseyinova, J. Baumert, and C. Meisinger
Prospective Study of High-Sensitivity C-Reactive Protein as a Determinant of Mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998
Clin. Chem.,
February 1, 2008;
54(2):
335 - 342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ben-Yehuda
High-Sensitivity C-Reactive Protein in Every Chart?: The Use of Biomarkers in Individual Patients
J. Am. Coll. Cardiol.,
May 29, 2007;
49(21):
2139 - 2141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
